Patents by Inventor Catherine L. Lawson

Catherine L. Lawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Altered OspA of
    Patent number: 8992936
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: March 31, 2015
    Assignees: Research Foundation of the State University of New York, Brookhaven Sciences Associates, LLC, University of Rochester
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
  • Altered OspA of
    Patent number: 8680236
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: March 25, 2014
    Assignees: Brookhaven Sciences Associates, LLC, University of Rochester, Research Foundation of the State University of New York
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
  • Altered OSPA of Borrelia Burgdorferi
    Publication number: 20140030285
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Application
    Filed: July 17, 2013
    Publication date: January 30, 2014
    Applicants: Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, University of Rochester
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
  • Altered ospa of borrelia burgdorferi
    Publication number: 20090326200
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Application
    Filed: November 19, 2008
    Publication date: December 31, 2009
    Applicants: Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, University of Rochester
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
  • Altered OspA of Borrelia burgdorferi
    Publication number: 20040023325
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Application
    Filed: February 18, 2003
    Publication date: February 5, 2004
    Applicants: Research Foundation of the State University of New York, Brookhaven Sciences Associates, LLC, University of Rochester
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson